First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

• Main Authors: Wu, Y.L., Zhou, C., Liam, C.K., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., Huang, C., Qin, S., Zhu, Y., Pan, H., Liang, H., Li, E., Jiang, G., How, S.H., Fernando, M.C.L., Zhang, Y., Xia, F., Zuo, Y.
• Format: Article
• Published: Oxford University Press 2015
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/19426/; http://dx.doi.org/10.1093/annonc/mdv270

Background: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Patien...